Skip to main content

Depression Treatment: A Lifelong Commitment?

Psychopharmacology Bulletin 36(Suppl. 2): 133-141, 2002/10/02; https://doi.org/10.64719/pb.6867

Abstract

Depression is associated with considerable disability, morbidity, and mortality. In many patients, depression follows a course of relapse and/or recurrence. However, there is significant evidence that the majority of patients with depressive disorders are undertreated, and this imposes a substantial economic burden on society. The reasons for undertreatment include patient, provider, and healthcare system factors. It is vital that treatment be targeted appropriately to break the cycle of relapse/recurrence. Rather than short-term improvement of symptoms, the optimal outcome of treatment of depressive disorders should be full symptom resolution (remission) and long-term recovery. Patients with histories of recurrent depressive episodes may require long-term, indefinite treatment with antidepressants. Currently, few data exist on the outcome and appropriate duration of maintenance pharmacotherapy. The benefits of psychotherapy have recently been demonstrated in a 12-week, randomized, controlled study, which also includes a maintenance phase that has not yet been completed. Additional well-designed studies addressing these issues are urgently needed.

Access This Article

Choose an access option below to view the full article.

Subscriber Access

If you or your institution has a subscription, log in to access this article.

Log In

Purchase Article

Buy single-article access with a one-time purchase.

$30.00
Add to Cart

How to Cite

Martin B. Keller, MD, and Ernst R. Berndt, PhD. Depression Treatment: A Lifelong Commitment?. Psychopharmacology Bulletin. 2002/10/02; 36(Suppl. 2):133-141. https://doi.org/10.64719/pb.6867